Boston, MA 05/13/2014 (wallstreetpr) – Halozyme Therapeutics (NASDAQ:HALO) is one of the leading companies in the US market, and due to its consistent market performance, the experts have considered it as premarket mover. There are several reasons behind it, for example-
- The average dollar volume which is nothing but the average daily volume multiplied with share price of HALO is $14.3 million.
- You don’t see every day that 169,894 shares of an individual company are traded in a single day, but it happened with HALO recently. It was 10.7% of total daily volume of the shares of the company.
HALO is active in health care and drug industry. The total market cap of the company is $882.6 million. The beta of the HALO is 1.97, and the short float of the company is 14.6% with a total period of 9.54 days to cover.
Opinion of Street rating Team:
The leading rating agency, the street rating team has given a ‘sell’ recommendation to the company. The company is week in many areas such as feeble growth and deteriorating net income which has resulted in negative stock performance. Some of the major points that the report given by street rating team include are-
- Halozyme Therapeutics (NASDAQ:HALO) has experienced 399.0% negative growth in the past one year. The net income of the company at the same time in the last year was -$4.41, while this year the company’s net income is -$21.99 million.
- The net earnings per share of the company has decreased over a period of one year.
- The revenues of the company have fallen significantly by a rate of 42.6%, which is far more than the industry rate of 25.9%.
So these are some of the reasons which have made the streetrating team opt to give ‘sell’ rating to Halozyme Therapeutics (NASDAQ:HALO).
